Search


Current filters:





Start a new search
Add filters:

Use filters to refine the search results.


Results 11-15 of 15 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2015TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsYeung, D.; Osborn, M.; White, D.; Branford, S.; Braley, J.; Herschtal, A.; Kornhauser, M.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Trotman, J.; Forsyth, C.; Taper, J.; Ross, D.; Beresford, J.; Tam, C.; et al.
2015Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch SyndromeAit Ouakrim, D.; Dashti, S.; Chau, R.; Buchanan, D.; Clendenning, M.; Rosty, C.; Winship, I.; Young, J.; Giles, G.; Leggett, B.; Macrae, F.; Ahnen, D.; Casey, G.; Gallinger, S.; Haile, R.; Le Marchand, L.; Thibodeau, S.; Lindor, N.; Newcomb, P.; Potter, J.; et al.
2015Fibrosis, gene expression and orbital inflammatory diseaseRosenbaum, J.; Choi, D.; Wilson, D.; Grossniklaus, H.; Harrington, C.; Dailey, R.; Ng, J.; Steele, E.; Czyz, C.; Foster, J.; Tse, D.; Alabiad, C.; Dubovy, S.; Parekh, P.; Harris, G.; Kazim, M.; Patel, P.; White, V.; Dolman, P.; Edward, D.; et al.
2015Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancerPeeters, M.; Oliner, K.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; André, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; He, P.; Yu, H.; Koukakis, R.; Terwey, J.; et al.
2015Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trialCADISS trial investigators,; Markus, H.; Hayter, E.; Levi, C.; Feldman, A.; Venables, G.; Norris, J.; Peycke, J.; Willson, M.; Hicks, C.; Hayter, E.; Madigan, J.; Clifton, A.; Menon, R.; Kennedy, F.; Khan, U.; Feldman, A.; Hollocks, M.; Markus, H.; King, A.; et al.